GlaxoSmithKline PLC's Avodart (dual 5-alpha-reductase inhibitor dutasteride which inhibits the conversion of testosterone into dihydrotesterone) cuts the risk of prostate cancer (and the same drug is also used to slow hair loss btw).
In the study, which involved 8,231 patients with increased risk of prostate cancer, 22.5% of men taking Avodart were diagnosed with prostate cancer after four years, compared with 29% who were taking a placebo.
But it did not cut the incidence of high grade tumors. Maybe those cancers were already present when Avodart dosing was started. Dutasteride might be better than finasteride (Proscar) for this purpose.
But wait, there's more. A big Mayo Clinic study found that statins seem to reduce the incidence of prostate cancer, erectile dysfunction and prostate enlargement.
Out of 26 men with recurrent prostate cancer, who took a daily dose of vitamin D2 bought from the chemist, five responded to the treatment.
In two the PSA level, fell by more than half, in two by 25-50% and in one man it fell by less than 25%.
The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less. These patients were treated by drinking eight ounces of pomegranate juice daily. Currently, in the sixth year of treatment, active patients who remain on the study have a median total follow-up of 56 months. These participants continue to experience a significant increase in PSA doubling time following treatment, from a mean of 15.4 months at baseline to 60 months post-treatment, with a median PSA slope decrease of 60 percent, 0.06 to 0.024.
One problem: I've yet to see pomegranate juice in a store.
So guys you've got drugs, a vitamin, and a juice to cut your risks of dying from prostate cancer.
|Share |||Randall Parker, 2009 April 28 12:47 AM Aging Diet Cancer Studies|